FTSE 100 today: Stocks down as Iran blockade fears eclipse upbeat earnings

Brent and WTI surged above $100 a barrel amid escalating U.S.-Iran tensions, continued Strait of Hormuz restrictions, and the UAE’s decision to exit OPEC, raising the risk of prolonged supply disruption and higher inflation. European equities were weaker, with the FTSE 100 down 0.6%, DAX down 0.2%, and CAC 40 down 0.4% as markets priced in geopolitical and energy shocks. UK company updates were mostly constructive — Lloyds beat Q1 profit expectations at £2 billion, AstraZeneca delivered $2.58 EPS on $15.29 billion revenue, and GSK topped forecasts — but the broader tone remained defensive due to Middle East uncertainty.

Analysis

This is a regime shift from a headline-driven spike to a potentially sticky input-cost shock. The market is underpricing how a prolonged choke point in seaborne barrels transmits into Europe first: refiners, airlines, chemicals, and consumer staples all face margin compression before the inflation impulse shows up in index prints. That matters because the first-order trade is energy longs, but the second-order trade is short duration-sensitive cyclicals and any business model with weak fuel pass-through.

The most important dynamic is dispersion within “defensive” equities. Large-cap pharma and healthcare with dollar revenues and limited energy intensity can actually gain relative appeal as macro volatility rises, while banks face a mixed setup: near-term NIM support from higher nominal rates, but rising credit-loss provisioning if energy shocks persist into a growth slowdown. For consumer names, the key question is not demand elasticity but working-capital stress; a sustained oil spike tends to squeeze gross margin before volumes roll over, which is more dangerous for mid-tier brands than for the global leaders.

The contrarian angle is that the market may be extrapolating the worst geopolitical case without fully pricing the policy response. A sustained >$100 oil print typically accelerates back-channel diplomacy and strategic supply releases, and producer coordination frays once prices become politically toxic. So the best risk/reward is not naked long energy here; it is owning the beneficiaries with cleaner balance sheets while fading the most energy-sensitive downstream sectors into strength.

For the named UK exposures, the earnings signal is mixed but useful: the strongest businesses can absorb the shock, while the weakest consumer franchises will likely see guidance pressure if the oil move lasts beyond a few weeks. Travel is the most exposed to a second-round hit, but near-term bookings can stay resilient until consumers actually see higher household bills. That sets up a lagged trade: the market may punish travel and discretionary names now, but the fundamental downdraft is more likely to show up in 1-2 quarters if Brent stays elevated.

Key Decisions for Investors

• Long AZN or GSK vs short a basket of European consumer/discretionary names for 4-8 weeks: pharma has lower energy intensity, stronger FX translation, and better defense if growth rolls over; target 2:1 risk/reward.
• Add tactical long energy exposure only through defined-risk structures: buy 1-2 month Brent call spreads or XLE call spreads to capture the next leg higher while capping downside if diplomacy or SPR rhetoric reverses the move.
• Short airlines/travel-adjacent equities on any relief rally; if the oil shock persists 2-6 weeks, fuel and demand mix pressure will hit margin assumptions before management teams can hedge around it.
• For LYG, trade it as a volatility beneficiary rather than a clean long: a long-dated call spread only works if higher rates persist without a sharp recession; otherwise the credit-cost risk dominates after a 1-2 quarter lag.
• Avoid chasing HLN near term; it is the least attractive of the named defensives because input-cost inflation can hit gross margin faster than revenue can reprice, making it a weaker relative short than the more cyclical consumer complex.